Team:TU Munich/Project/Xanthohumol

From 2012.igem.org

(Difference between revisions)
(BioBricks)
(Overview)
 
(37 intermediate revisions not shown)
Line 1: Line 1:
{{Team:TU_Munich/Header}}
{{Team:TU_Munich/Header}}
 +
 +
{{Team:TU_Munich/ExCol}}
= Xanthohumol =
= Xanthohumol =
Line 7: Line 9:
Flavonoids are valuable natural products with '''anti-inflammatory''', '''antiallergenic''' and '''antioxidant''' activities in humans. For the chemical synthesis of flavonoids, extreme reaction conditions and toxic chemicals are required. Hence, we chose the transfer of this metabolic pathway into ''Saccharomyces cerevisiae'' as an attractive alternative source of flavonoids.
Flavonoids are valuable natural products with '''anti-inflammatory''', '''antiallergenic''' and '''antioxidant''' activities in humans. For the chemical synthesis of flavonoids, extreme reaction conditions and toxic chemicals are required. Hence, we chose the transfer of this metabolic pathway into ''Saccharomyces cerevisiae'' as an attractive alternative source of flavonoids.
-
After the successful implementation of the first steps of the phenylpropanoid pathway, the synthesis of different flavonoids are conceivable. Besides '''raspberry ketone''', the aroma compound of rasperries, plant substances with benifical to ones life can be synthesized, for example '''resveratrol''' or '''xanthohumol''', which we will focus on.  
+
After the successful implementation of the first steps of the phenylpropanoid pathway, the syntheses of different flavonoids are conceivable. Along with '''raspberry ketone''', the aroma compound of raspberries, plant substances providing beneficial effects to ones life could be synthesized, for example '''resveratrol''' or '''xanthohumol''', which we will focus on.  
We successfully cloned all enzymes necessary for the pathway of xanthohumol in the new yeast expression vector [http://partsregistry.org/Part:BBa_K801004 pTUM104]. Every gene was sequenced and submitted as a BioBrick. So we established BioBricks in order to produce xanthohumol in yeast ([http://partsregistry.org/wiki/index.php?title=Part:BBa_K801090 BBa_K801090], [http://partsregistry.org/wiki/index.php?title=Part:BBa_K801091 BBa_K801091], [http://partsregistry.org/wiki/index.php?title=Part:BBa_K801092 BBa_K801092], [http://partsregistry.org/wiki/index.php?title=Part:BBa_K801093 BBa_K801093], [http://partsregistry.org/wiki/index.php?title=Part:BBa_K801094 BBa_K801094], [http://partsregistry.org/wiki/index.php?title=Part:BBa_K801095 BBa_K801095], [http://partsregistry.org/wiki/index.php?title=Part:BBa_K801096 BBa_K801096], [http://partsregistry.org/wiki/index.php?title=Part:BBa_K801097 BBa_K801097], [http://partsregistry.org/wiki/index.php?title=Part:BBa_K801098 BBa_K801098],).
We successfully cloned all enzymes necessary for the pathway of xanthohumol in the new yeast expression vector [http://partsregistry.org/Part:BBa_K801004 pTUM104]. Every gene was sequenced and submitted as a BioBrick. So we established BioBricks in order to produce xanthohumol in yeast ([http://partsregistry.org/wiki/index.php?title=Part:BBa_K801090 BBa_K801090], [http://partsregistry.org/wiki/index.php?title=Part:BBa_K801091 BBa_K801091], [http://partsregistry.org/wiki/index.php?title=Part:BBa_K801092 BBa_K801092], [http://partsregistry.org/wiki/index.php?title=Part:BBa_K801093 BBa_K801093], [http://partsregistry.org/wiki/index.php?title=Part:BBa_K801094 BBa_K801094], [http://partsregistry.org/wiki/index.php?title=Part:BBa_K801095 BBa_K801095], [http://partsregistry.org/wiki/index.php?title=Part:BBa_K801096 BBa_K801096], [http://partsregistry.org/wiki/index.php?title=Part:BBa_K801097 BBa_K801097], [http://partsregistry.org/wiki/index.php?title=Part:BBa_K801098 BBa_K801098],).
Line 15: Line 17:
-
==Background and principles==
+
==Background and Principles==
----
----
-
[[File:TUM12_4-coumaroyl_CoA.jpg|right|thumb|200px| '''4-coumaroyl-CoA''']]
+
[[File:TUM12_4-coumaroyl_CoA.jpg|right|thumb|300px| '''Fig. 1: Structure of 4-coumaroyl-CoA.''']]
-
 
+
-
 
+
-
 
+
-
 
+
-
Plant secondary metabolites have proven or assumed beneficial properties and health promoting effects. Stilbenoids, flavonoids or lignins can result from 4-coumaroyl-coenzyme A, which is a nodal compound of phenylproponaoid metabolism in plants. 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
 +
Plant secondary metabolites have proven or assumed beneficial properties and health promoting effects. Stilbenoids, flavonoids or lignins can result from 4-coumaroyl-coenzyme A (see Fig. 1), which is a nodal compound of the phenylproponaoid metabolism in plants. 
 +
<div style="clear:both">
===Biosynthesis===
===Biosynthesis===
 +
</div>
<div>
<div>
-
[[File:TUM12_Biosynthesis_of_Xanthohumol.png|right|thumb|300px| '''Biosynthesis of Xanthohumol''']]
+
[[File:TUM12_Biosynthesis_of_Xanthohumol.png|right|thumb|300px| '''Fig. 2: Biosynthesis of xanthohumol.''']]
-
The biosynthetic pathway of 4-coumaroyl-coenzyme A starts with the conversion of L-Phenylalanine to cinnamate catalyzed by phenylalanin ammonia lyase (PAL) ['''A''']. PAL also shows activity with converting tyrosine to p-coumarate, albeit to a lower efficiency ['''B''']. The cinnamate 4-hydroxylase (C4H) catalyzes the synthesis of p-hydroxycinnamate from cinnamate and 4-coumarate ['''C''']: CoA ligase (4CL) converts p-coumarate to its coenzyme-A ester, activating it for reaction with malonyl CoA ['''D''']  [[http://www.ncbi.nlm.nih.gov/pubmed/19631278 Trantas ''et al.'', 2009]].
+
The biosynthetic pathway of 4-coumaroyl-coenzyme A starts with the conversion of L-Phenylalanine to cinnamate, being catalyzed by phenylalanin ammonia lyase (PAL) ['''A''']. PAL also shows activity in converting tyrosine to p-coumarate, but with a lower efficiency ['''B''']. The cinnamate 4-hydroxylase (C4H) catalyzes the synthesis of p-hydroxycinnamate from cinnamate and 4-coumarate ['''C''']: CoA ligase (4CL) converts p-coumarate to its coenzyme-A ester, activating it for reaction with malonyl CoA ['''D''']  [[http://www.ncbi.nlm.nih.gov/pubmed/19631278 Trantas ''et al.'', 2009]].
-
The flavonoid biosynthetic pathway starts with the condensation of one molecule of 4-coumaroyl-CoA and three molecules of malonyl-CoA, yielding naringenin chalcone. This reaction is carried out by the enzyme chalcone synthase (CHS) ['''E''']. Chalcone is isomerised to a flavanone by the enzyme chalcone flavanone isomerase (CHI). From these central intermediates, the pathway diverges into several side branches, each resulting in a different class of flavonoids, for example Xanthohumol.
+
The flavonoid biosynthetic pathway starts with the condensation of one molecule of 4-coumaroyl-CoA and three molecules of malonyl-CoA, yielding naringenin chalcone. This reaction is carried out by the enzyme chalcone synthase (CHS) ['''E''']. Chalcone is isomerised to a flavanone by the enzyme chalcone flavanone isomerase (CHI). From these central intermediates, the pathway diverges into several side branches, each resulting in a different class of flavonoids, such as xanthohumol.
-
Our project will focus on the '''production of Xanthohumol''', due to its characteristic as a cancer chemopreventive agent (see below).
+
Our project will focus on the '''production of xanthohumol''' (see Fig. 3), due to its characteristic as a cancer chemopreventive agent (see below).
-
The idea is to perform a heterologous gene expression of all enzymes required for Xanthohumol biosynthesis in ''Saccharomyces cerevisiae''. First, each enzyme should be expressed individually and the activities should be tested individually to ensure the functionality. Each gene should be inserted in a yeast expression vector under the control of a GAL1 promotor.  
+
The idea is to perform a heterologous gene expression of all enzymes required for xanthohumol biosynthesis in ''Saccharomyces cerevisiae''. First, each enzyme should be expressed individually, with the activities being also tested individually to ensure the functionality. Each gene should be inserted in a yeast expression vector under the control of a GAL1 promotor.  
-
The final goal is the expression of all required genes in a single modified yeast to produce Xanthohumol out of the substrate L-Tyrosin.
+
The final goal is the expression of all required genes in a single modified yeast-stem to produce xanthohumol out of the substrate L-Tyrosin.
</div>
</div>
-
There are 5 enzymes necessary for the '''biosynthesis of Xanthohumol''' ([http://biocyc.org/META/NEW-IMAGE?type=NIL&object=PWY-5135 MetaCyc]):
+
There are 5 enzymes necessary for the '''biosynthesis of xanthohumol''' (see Fig. 2) ([http://biocyc.org/META/NEW-IMAGE?type=NIL&object=PWY-5135 MetaCyc]):
Enzyme ['''A''']: PAL = phenylalanine ammonia lyase:    L-phenylalanin --> trans-cinnamate
Enzyme ['''A''']: PAL = phenylalanine ammonia lyase:    L-phenylalanin --> trans-cinnamate
Line 54: Line 48:
Enzyme ['''G''']: OMT1 = chalcone O-methyltransferase:    desmethylxanthohumol --> xanthohumol
Enzyme ['''G''']: OMT1 = chalcone O-methyltransferase:    desmethylxanthohumol --> xanthohumol
-
Jiang et al succeed in the biosynthesis of several flavonoids in ''Saccharomyces cerevisiae'' by the assembly of a plasmid which contains three required enzymes (pKS2µHyg-PAL-4CL-CHS) and showed thereby the '''proof of principle'''. The activity of each enzyme was demonstrated and the presence of naringenin, which forms the product of the three enzymes( PAL, 4CL, CHS) was shown.
+
Jiang et al succeeded in the biosynthesis of several flavonoids in ''Saccharomyces cerevisiae'' by the assembly of a plasmid containing three required enzymes (pKS2µHyg-PAL-4CL-CHS) and thereby showed the '''proof of principle'''. The activity of each enzyme was demonstrated and the presence of naringenin, which forms the product of the three enzymes( PAL, 4CL, CHS), was shown.
[[http://www.ncbi.nlm.nih.gov/pubmed/14704995 Jiang and Morgan, 2004]]
[[http://www.ncbi.nlm.nih.gov/pubmed/14704995 Jiang and Morgan, 2004]]
-
===The molecular and physiological effects of xanthohumol===
+
===The Molecular and Physiological Effects of Xanthohumol===
<div>
<div>
-
[[File:TUM12_Xanthohumol.png|right|thumb|200px| '''Xanthohumol''']]  
+
[[File:TUM12_Xanthohumol.png|right|thumb|200px| '''Fig. 3: Structure of xanthohumol.''']]  
-
====Inhibition of the metabolic activation of procarcinogens: ====
+
====Inhibition of Metabolic Activation of Procarcinogens: ====
-
2-amino-3-methylimidazo[4,5-f]quinolone, found in cooked meat, verified as a procarcinogen in an ames salmonella mutagenicity test. The inhibition is probably a result of an inhibition of the cytochrome P 450 enzymes Cyp1A1, Cyp1B1 and Cyp1A2 (phase 1 enzymes). But in order to achieve a clear inhibition, plasma concentrations of 1 µM would be necessary. In a study with male rats oral administration of xanthohumol (50 mg/kg) led to concentration maximums of 65 -180 nM after 4 h. Improved resorption of Xanthohumol could be a possible target for innovation ([http://www.ncbi.nlm.nih.gov/pubmed/11240137 Yilmazer ''et al.'' 2001], [http://www.ncbi.nlm.nih.gov/pubmed/10995285 Miranda ''et al.'' 2000], [http://www.ncbi.nlm.nih.gov/pubmed/10752639 Henderson ''et al.'', 2000], [http://www.ncbi.nlm.nih.gov/pubmed/12481418 Gerhauser ''et al.'', 2002]).
+
2-amino-3-methylimidazo[4,5-f]quinolone, found in cooked meat, verified as a procarcinogen in an ames salmonella mutagenicity test. The inhibition is probably a result of an inhibition of the cytochrome P 450 enzymes Cyp1A1, Cyp1B1 and Cyp1A2 (phase 1 enzymes). But in order to achieve a clear inhibition, plasma concentrations of 1 µM would be necessary. In a study with male rats oral administration of xanthohumol (50 mg/kg) led to concentration maximums of 65 -180 nM after 4 h. Improved resorption of xanthohumol could be a possible target for innovation [[http://www.ncbi.nlm.nih.gov/pubmed/11240137 Yilmazer ''et al.'' 2001a], [http://www.ncbi.nlm.nih.gov/pubmed/10995285 Miranda ''et al.'' 2000b], [http://www.ncbi.nlm.nih.gov/pubmed/10752639 Henderson ''et al.'', 2000], [http://www.ncbi.nlm.nih.gov/pubmed/12481418 Gerhauser ''et al.'', 2002]].
-
====Induction of carcinogen-detoxifying enzymes (phase 2 enzymes): ====
+
====Induction of Carcinogen-Detoxifying Enzymes (Phase 2 Enzymes): ====
-
P450-activated carcinogens get conjugated to endogenous ligands (gluthathione, glucoronic acid, acetate and sulfate) by phase 2 enzymes to facilitate excretion. Therefore the induction of phase 2 enzymes should enhance the protection against carcinogenesis. Xanthohumol cat concentrations of 2.1-10.1 µM could induce quinone reductase (detoxification of quinones by ceonversion to hydroquinones which can be conjugated) in hepatoma Hepa 1c1c7 cells. It was shown that xanthohumol could selectively induce quinone reductase without causing a transcriptional activation of Cyp1A1 ([http://www.ncbi.nlm.nih.gov/pubmed/11038156 Miranda ''et al.'', 2000], [http://www.ncbi.nlm.nih.gov/pubmed/12481418 Gerhauser ''et al.'', 2002]).
+
P450-activated carcinogens get conjugated to endogenous ligands (gluthathione, glucoronic acid, acetate and sulfate) by phase 2 enzymes to facilitate excretion. Therefore the induction of phase 2 enzymes should enhance the protection against carcinogenesis. Xanthohumol cat concentrations of 2.1-10.1 µM could induce quinone reductase (detoxification of quinones by conversion to hydroquinones which can be conjugated) in hepatoma Hepa 1c1c7 cells. It was shown that xanthohumol could selectively induce quinone reductase without causing a transcriptional activation of Cyp1A1 [[http://www.ncbi.nlm.nih.gov/pubmed/11038156 Miranda ''et al.'', 2000c], [http://www.ncbi.nlm.nih.gov/pubmed/12481418 Gerhauser ''et al.'', 2002]].
-
====Inhibition of tumor growth at an early stage:====
+
====Inhibition of Tumor Growth at an Early Stage:====
-
Xantohumol showed an inhibition of the proliferation of breast cancer (MCF-7) and ovarian cancer (A-2780) in vitro at IC50 values of 13 and 0.52 µM ([http://www.ncbi.nlm.nih.gov/pubmed/10418944 Miranda ''et al.'', 1999]). Furthermore xanthohumol can inhibit the endogenous prostaglandin synthesis through inhibition of cyclooxygenase (COX-1 and COX-2) with IC50 values of 17 and 42 µM. An increased prostaglandin production has been associated with the uncontrolled proliferation of tumor cells ([http://www.ncbi.nlm.nih.gov/pubmed/12481418 Gerhauser ''et al.'', 2002]).
+
Xanthohumol showed an inhibition of the proliferation of breast cancer (MCF-7) and ovarian cancer (A-2780) in vitro at IC50 values of 13 and 0.52 µM [[http://www.ncbi.nlm.nih.gov/pubmed/10418944 Miranda ''et al.'', 1999]]. Furthermore xanthohumol can inhibit the endogenous prostaglandin synthesis through inhibition of cyclooxygenase (COX-1 and COX-2) with IC50 values of 17 and 42 µM. An increased prostaglandin production has been associated with the uncontrolled proliferation of tumor cells [[http://www.ncbi.nlm.nih.gov/pubmed/12481418 Gerhauser ''et al.'', 2002]].
Pharmacokinetic studies for xanthohumol based on beverages with an xanthohumol content of 50 mg/l in humans are part of actual research activities.
Pharmacokinetic studies for xanthohumol based on beverages with an xanthohumol content of 50 mg/l in humans are part of actual research activities.
-
====Antioxidant activities: ====
+
====Antioxidant Activities: ====
-
Xanthohumol at 5 µM decreased conjugated diene formation as a measure for lipid peroxidation by more than 70 % after 5 h of incubation in an in vitro assay (protection of LDL from Cu2+ induced oxidation). Furthermore Xanthohumol was shown to scavenge hydroxyl-, peroxyl- and superoxide anion radicals ([http://www.ncbi.nlm.nih.gov/pubmed/11038156 Miranda ''et al.'', 2000]).
+
Xanthohumol at 5 µM decreased conjugated diene formation as a measure for lipid peroxidation by more than 70 % after 5 h of incubation in an in vitro assay (protection of LDL from Cu2+ induced oxidation). Furthermore xanthohumol was shown to scavenge hydroxyl-, peroxyl- and superoxide anion radicals [[http://www.ncbi.nlm.nih.gov/pubmed/11038156 Miranda ''et al.'', 2000c]].
</div>
</div>
Line 79: Line 73:
===BioBricks===
===BioBricks===
-
The following BioBricks were constructed to achieve the production of xantohumol.
+
The following BioBricks were constructed to achieve the production of xanthohumol.
-
 
-
<div class="mleft bezel">
 
==== Overview====
==== Overview====
-
[[File:TUM12 experiment overwiew xanto2.png|center|300px]]
+
[[File:TUM12 experiment overwiew xanto2.png|thumb|center|800px|'''Fig. 4: Metabolic pathway of xanthohumol and designed BioBricks.''']]
-
</div>
+
 
 +
 
 +
<div class="mfull bezel">
-
<div class="mright bezel">
+
==== [http://partsregistry.org/Part:BBa_K801090 BBa_K801090] and [http://partsregistry.org/Part:BBa_K801091 BBa_K801091] RFC10 compatible BioBricks encoding the enzyme PAL ====
-
==== [http://partsregistry.org/Part:BBa_K801090 BBa_K801090] and [http://partsregistry.org/Part:BBa_K801091 BBa_K801091]====
+
-
Both RFC10 compatible BioBricks encode the enzyme phenylalanine ammonia lyase (PAL). BBa_K801090 contains the yeast consensus sequence (improved ribosome binding), BBa_K801091 does not.  PAL is catalyzing the first reaction step of the xantohumol biosynthesis pathway resulting in 4-coumarate.  
+
Both RFC10 compatible BioBricks encode the enzyme phenylalanine ammonia lyase (PAL). BBa_K801090 contains the yeast consensus sequence (improved ribosome binding), BBa_K801091 does not.  PAL is catalyzing the first reaction step of the xanthohumol biosynthesis pathway resulting in 4-coumarate.  
-
'''Further information:'''
+
'''Further Information:'''
* [http://www.ncbi.nlm.nih.gov/nuccore/AX366866 NCBI]
* [http://www.ncbi.nlm.nih.gov/nuccore/AX366866 NCBI]
* UniProt entry: P11544
* UniProt entry: P11544
Line 98: Line 91:
* Origin of the enzyme: ''Rhodosporidium toruloides''
* Origin of the enzyme: ''Rhodosporidium toruloides''
</div>
</div>
-
<div class="mleft bezel">
+
<div class="mfull bezel">
-
==== [http://partsregistry.org/Part:BBa_K801092 BBa_K801092] and [http://partsregistry.org/Part:BBa_K801093 BBa_K801093] ====
+
==== [http://partsregistry.org/Part:BBa_K801092 BBa_K801092] and [http://partsregistry.org/Part:BBa_K801093 BBa_K801093] RFC25 compatible BioBricks encode the enzyme 4CL====
Both RFC25 compatible BioBricks encode the enzyme 4-coumarate-coenzyme A ligase (4CL). BBa_K801092 contains the yeast consensus sequence, BBa_K801093 does not.   
Both RFC25 compatible BioBricks encode the enzyme 4-coumarate-coenzyme A ligase (4CL). BBa_K801092 contains the yeast consensus sequence, BBa_K801093 does not.   
-
'''Further information:'''
+
'''Further Information:'''
* [http://www.ncbi.nlm.nih.gov/nucleotide/609339/ NCBI]
* [http://www.ncbi.nlm.nih.gov/nucleotide/609339/ NCBI]
* UniProt entry: Q42524
* UniProt entry: Q42524
Line 110: Line 103:
* Origin of the enzyme: ''Arabidopsis thaliana''
* Origin of the enzyme: ''Arabidopsis thaliana''
</div>
</div>
-
<div class="mright bezel">
+
<div class="mfull bezel">
-
==== [http://partsregistry.org/Part:BBa_K801094 BBa_K801094] and [http://partsregistry.org/Part:BBa_K801095 BBa_K801095] ====
+
 
 +
==== [http://partsregistry.org/Part:BBa_K801094 BBa_K801094] and [http://partsregistry.org/Part:BBa_K801095 BBa_K801095] RFC25 compatible BioBricks encoding the enzyme CHS====
Both RFC25 compatible BioBricks encode the enzyme naringenin-chalcone synthase (CHS). BBa_K801094 contains the yeast consensus sequence, BBa_K801095 does not.   
Both RFC25 compatible BioBricks encode the enzyme naringenin-chalcone synthase (CHS). BBa_K801094 contains the yeast consensus sequence, BBa_K801095 does not.   
-
'''Further information:'''
+
'''Further Information:'''
* [http://www.ncbi.nlm.nih.gov/nucleotide/11096318/ NCBI]
* [http://www.ncbi.nlm.nih.gov/nucleotide/11096318/ NCBI]
* UniProt entry: Q9FUB7
* UniProt entry: Q9FUB7
Line 121: Line 115:
* Origin of the enzyme: ''Hypericum androsaemum''
* Origin of the enzyme: ''Hypericum androsaemum''
</div>
</div>
-
<div class="mleft bezel">
+
<div class="mfull bezel">
-
==== [http://partsregistry.org/Part:BBa_K801096 BBa_K801096] ====
+
 
 +
==== [http://partsregistry.org/Part:BBa_K801096 BBa_K801096] RFC25 compatible BioBrick encoding the enzyme APT ====
This RFC25 compatible BioBrick encodes the enzyme aromatic prenyltransferase (APT).  
This RFC25 compatible BioBrick encodes the enzyme aromatic prenyltransferase (APT).  
-
'''Further information:'''
+
'''Further Information:'''
* [http://www.ncbi.nlm.nih.gov/nuccore/AB543053 NCBI]
* [http://www.ncbi.nlm.nih.gov/nuccore/AB543053 NCBI]
* UniProt entry: E5RP65
* UniProt entry: E5RP65
Line 132: Line 127:
* Origin of the enzyme: ''Humulus lupulus''
* Origin of the enzyme: ''Humulus lupulus''
</div>
</div>
-
<div class="mright bezel">
+
<div class="mfull bezel">
-
==== [http://partsregistry.org/Part:BBa_K801097 BBa_K801097] and [http://partsregistry.org/Part:BBa_K801098 BBa_K801098] ====
+
 
 +
==== [http://partsregistry.org/Part:BBa_K801097 BBa_K801097] and [http://partsregistry.org/Part:BBa_K801098 BBa_K801098] RFC25 compatible BioBricks encoding the enzyme OMT1 ====
Both RFC25 compatible BioBricks encode the enzyme O-methyltransferase 1 (OMT1). BBa_K801097 contains the yeast consensus sequence, BBa_K801095 does not.   
Both RFC25 compatible BioBricks encode the enzyme O-methyltransferase 1 (OMT1). BBa_K801097 contains the yeast consensus sequence, BBa_K801095 does not.   
-
'''Further information:'''
+
'''Further Information:'''
* [http://www.ncbi.nlm.nih.gov/nucleotide/167613934/ NCBI]
* [http://www.ncbi.nlm.nih.gov/nucleotide/167613934/ NCBI]
* UniProt entry: B0ZB55
* UniProt entry: B0ZB55
Line 148: Line 144:
</div>
</div>
----
----
-
We have successfully cloned all 5 enzymes which are necessary for the biosynthesis of Xantohumol in [http://partsregistry.org/Part:BBa_K801004 pTUM104] as well as in pSB1C3. Except for APT each enzyme was designed in two versions:  one with a proposed yeast consensus sequence and one without.  In yeast this sequence should result in improved ribosome binding (TACACA) and was added 5’ of the start codon ATG. All BioBricks were sequenced. Sequences can be found in the registry of standard biological parts: '''!!!LINK: get selected sequence''' [ BBa_K801090], [ BBa_K801091], [ BBa_K801092], [ BBa_K801093], [ BBa_K801094], [ BBa_K801095], [ BBa_K801096], [ BBa_K801097], [ BBa_K801098].
+
We have successfully cloned all 5 enzymes which are necessary for the biosynthesis of xanthohumol in [http://partsregistry.org/Part:BBa_K801004 pTUM104] as well as in pSB1C3. Except for APT each enzyme was designed in two versions:  one with a proposed yeast consensus sequence and one without.  In yeast this sequence should result in improved ribosome binding (TACACA) and was added 5’ of the start codon ATG. All BioBricks were sequenced. Sequences can be found in the registry of standard biological parts:  
 +
[http://partsregistry.org/Part:BBa_K801090 BBa_K801090],  
 +
[http://partsregistry.org/Part:BBa_K801091 BBa_K801091],  
 +
[http://partsregistry.org/Part:BBa_K801092 BBa_K801092],  
 +
[http://partsregistry.org/Part:BBa_K801093 BBa_K801093],  
 +
[http://partsregistry.org/Part:BBa_K801094 BBa_K801094],  
 +
[http://partsregistry.org/Part:BBa_K801095 BBa_K801095],  
 +
[http://partsregistry.org/Part:BBa_K801096 BBa_K801096],  
 +
[http://partsregistry.org/Part:BBa_K801097 BBa_K801097],  
 +
[http://partsregistry.org/Part:BBa_K801098 BBa_K801098].
Line 165: Line 170:
*[[http://www.ncbi.nlm.nih.gov/pubmed/11240137 Yilmazer et al., 2001a]] Yilmazer, M., Stevens, J. F., and Buhler, D. R. (2001a). In vitro glucuronidation of xanthohumol, a flavonoid in hop and beer, by rat and human liver microsomes. ''FEBS Lett'', 491(3):252–6.
*[[http://www.ncbi.nlm.nih.gov/pubmed/11240137 Yilmazer et al., 2001a]] Yilmazer, M., Stevens, J. F., and Buhler, D. R. (2001a). In vitro glucuronidation of xanthohumol, a flavonoid in hop and beer, by rat and human liver microsomes. ''FEBS Lett'', 491(3):252–6.
*[[http://www.ncbi.nlm.nih.gov/pubmed/11181488 Yilmazer et al., 2001b]] Yilmazer, M., Stevens, J. F., Deinzer, M. L., and Buhler, D. R. (2001b). In vitro biotransformation of xanthohumol, a flavonoid from hops (''Humulus lupulus''), by rat liver microsomes. ''Drug Metab Dispos'', 29(3):223–31.
*[[http://www.ncbi.nlm.nih.gov/pubmed/11181488 Yilmazer et al., 2001b]] Yilmazer, M., Stevens, J. F., Deinzer, M. L., and Buhler, D. R. (2001b). In vitro biotransformation of xanthohumol, a flavonoid from hops (''Humulus lupulus''), by rat liver microsomes. ''Drug Metab Dispos'', 29(3):223–31.
-
 
-
 
-
==older blocks==
 
-
 
-
 
-
 
-
==General Remarks==
 
-
----
 
-
<div>
 
-
[[File:TUM12_Jiang_detailofpaper.png|right|thumb|300px| '''Detail of Jiang et al., 2004''']]
 
-
 
-
 
-
 
-
 
-
===Enzyme 1: phenylalanine ammonia lyase (PAL)===
 
-
<div>
 
-
'''Compatibility (iGEM and ''S. cerevisiae'')'''
 
-
{| class="wikitable" cellpadding="10" border=1px
 
-
| Name || Length || RFC10 || RFC25 || Codon Usage || NCBI
 
-
|-
 
-
| Phenylalanine ammonia lyase || 2439bp bzw. 2151bp || ok || 6xNgoMIV (1438,1684,1852,1995,2329) || 0 AS<10% || [http://www.ncbi.nlm.nih.gov/nuccore/AX366866]
 
-
|}
 
-
 
-
 
-
'''Purification and Assay'''
 
-
{| class="wikitable" cellpadding="10" border=1px
 
-
| Name || used restriction sites || purification || assay
 
-
|-
 
-
| Phenylalanine ammonia lyase || XbaI, AgeI || Strep tag II || substrate: L-tyrosin, product: 4-coumarate
 
-
|}
 
-
</div>
 
-
===Enzyme 2: 4-coumarate - coenzym A ligase (4CL)===
 
-
<div>
 
-
'''Compatibility (iGEM and ''S. cerevisiae'')'''
 
-
{| class="wikitable" cellpadding="10" border=1px
 
-
| Name || Length || RFC10 || RFC25 || Codon Usage || NCBI
 
-
|-
 
-
| Arabidopsis thaliana 4-coumarate--coenzyme A ligase || 1869 bp bzw. 1685 bp || ok || ok after RFC10 || 0 AS<10% || [http://www.ncbi.nlm.nih.gov/nucleotide/609339/]
 
-
|}
 
-
 
-
 
-
'''Purification and Assay'''
 
-
{| class="wikitable" cellpadding="10" border=1px
 
-
| Name || used restriction sites || purification || assay 
 
-
|-
 
-
| Arabidopsis thaliana 4-coumarate--coenzyme A ligase || XbaI, PstI || crude protein extraction || substrate: 4-coumarate, product: 4-coumaryl-CoA
 
-
|}
 
-
</div>
 
-
=== Enzyme 3: naringenin - chalcone synthase(CHS)===
 
-
<div>
 
-
'''Compatibility (iGEM and ''S. cerevisiae'')'''
 
-
{| class="wikitable" cellpadding="10" border=1px
 
-
| Name || Length || RFC10 || RFC25 || Codon Usage || NCBI
 
-
|-
 
-
| Hypericum androsaemum chalcone synthase || 1402 bp || ok || ok after RFC10 || 2 AS<10% ||
 
-
[http://www.ncbi.nlm.nih.gov/nucleotide/11096318/]
 
-
|}
 
-
 
-
 
-
'''Purification and Assay'''
 
-
{| class="wikitable" cellpadding="10" border=1px
 
-
| Name || used restriction sites || purification || assay 
 
-
|-
 
-
| Hypericum androsaemum chalcone synthase || XbaI, AgeI || Strep tag II || subtrate:
 
-
|}
 
-
</div>
 
-
=== Enzyme 4: aromatic prenyltransferase (APT) ===
 
-
<div>
 
-
'''Compatibility (iGEM and ''S. cerevisiae'')'''
 
-
{| class="wikitable" cellpadding="10" border=1px
 
-
| Name || Length || RFC10 || RFC25 || Codon Usage || NCBI
 
-
|-
 
-
| Humulus lupulus aromatic prenyltransferase || 1236 bp || ok  || ok  || optimized by GeneArt ||
 
-
[http://www.ncbi.nlm.nih.gov/nuccore/AB543053]
 
-
|}
 
-
 
-
 
-
'''Purification and Assay'''
 
-
{| class="wikitable" cellpadding="10" border=1px
 
-
| Name || used restriction sites || purification || assay 
 
-
|-
 
-
| Humulus lupulus aromatic prenyltransferase || XbaI, AgeI || Strep tag II || substrate:
 
-
|}
 
-
</div>
 
-
=== Enzyme 5: chalcone O-methyltransferase(OMT1) ===
 
-
<div>
 
-
'''Compatibility (iGEM and ''S. cerevisiae'')'''
 
-
{| class="wikitable" cellpadding="10" border=1px
 
-
| Name || Length || RFC10 || RFC25 || Codon Usage || NCBI
 
-
|-
 
-
| Humulus lupulus O-methyltransferase 1  || 1058  || ok || ok || 2 AS<10% ||
 
-
[http://www.ncbi.nlm.nih.gov/nucleotide/167613934/]
 
-
|}
 
-
 
-
 
-
'''Purification and Assay'''
 
-
{| class="wikitable" cellpadding="10" border=1px
 
-
| Name || used restriction sites || purification || assay 
 
-
|-
 
-
| Humulus lupulus O-methyltransferase 1  || XbaI, AgeI || Strep tag II || subtrate:
 
-
|}
 
-
 
-
</div>
 

Latest revision as of 19:27, 26 October 2012


Contents

Xanthohumol


Responsible: Daniela Dichtler, Ingmar Polte, Maria Trumpfheller and Katrin Fischer

Flavonoids are valuable natural products with anti-inflammatory, antiallergenic and antioxidant activities in humans. For the chemical synthesis of flavonoids, extreme reaction conditions and toxic chemicals are required. Hence, we chose the transfer of this metabolic pathway into Saccharomyces cerevisiae as an attractive alternative source of flavonoids. After the successful implementation of the first steps of the phenylpropanoid pathway, the syntheses of different flavonoids are conceivable. Along with raspberry ketone, the aroma compound of raspberries, plant substances providing beneficial effects to ones life could be synthesized, for example resveratrol or xanthohumol, which we will focus on.

We successfully cloned all enzymes necessary for the pathway of xanthohumol in the new yeast expression vector pTUM104. Every gene was sequenced and submitted as a BioBrick. So we established BioBricks in order to produce xanthohumol in yeast (BBa_K801090, BBa_K801091, BBa_K801092, BBa_K801093, BBa_K801094, BBa_K801095, BBa_K801096, BBa_K801097, BBa_K801098,).

Our next goals are to proof the expression of every single enzyme by Western Blot Analysis and to show the functionality with established enzyme assays.


Background and Principles


Fig. 1: Structure of 4-coumaroyl-CoA.

Plant secondary metabolites have proven or assumed beneficial properties and health promoting effects. Stilbenoids, flavonoids or lignins can result from 4-coumaroyl-coenzyme A (see Fig. 1), which is a nodal compound of the phenylproponaoid metabolism in plants.

Biosynthesis

Fig. 2: Biosynthesis of xanthohumol.

The biosynthetic pathway of 4-coumaroyl-coenzyme A starts with the conversion of L-Phenylalanine to cinnamate, being catalyzed by phenylalanin ammonia lyase (PAL) [A]. PAL also shows activity in converting tyrosine to p-coumarate, but with a lower efficiency [B]. The cinnamate 4-hydroxylase (C4H) catalyzes the synthesis of p-hydroxycinnamate from cinnamate and 4-coumarate [C]: CoA ligase (4CL) converts p-coumarate to its coenzyme-A ester, activating it for reaction with malonyl CoA [D] [Trantas et al., 2009].

The flavonoid biosynthetic pathway starts with the condensation of one molecule of 4-coumaroyl-CoA and three molecules of malonyl-CoA, yielding naringenin chalcone. This reaction is carried out by the enzyme chalcone synthase (CHS) [E]. Chalcone is isomerised to a flavanone by the enzyme chalcone flavanone isomerase (CHI). From these central intermediates, the pathway diverges into several side branches, each resulting in a different class of flavonoids, such as xanthohumol.

Our project will focus on the production of xanthohumol (see Fig. 3), due to its characteristic as a cancer chemopreventive agent (see below). The idea is to perform a heterologous gene expression of all enzymes required for xanthohumol biosynthesis in Saccharomyces cerevisiae. First, each enzyme should be expressed individually, with the activities being also tested individually to ensure the functionality. Each gene should be inserted in a yeast expression vector under the control of a GAL1 promotor. The final goal is the expression of all required genes in a single modified yeast-stem to produce xanthohumol out of the substrate L-Tyrosin.

There are 5 enzymes necessary for the biosynthesis of xanthohumol (see Fig. 2) (MetaCyc):

Enzyme [A]: PAL = phenylalanine ammonia lyase: L-phenylalanin --> trans-cinnamate

Enzyme [D]: 4CL = 4-coumarate - coenzym A ligase: 4-coumarate --> 4-coumaroyl-CoA

Enzyme [E]: CHS = naringenin - chalcone synthase: 4-coumaroyl-CoA --> naringeninchalcone

Enzyme [F]: APT = aromatic prenyltransferase: naringeninchalcone --> desmethylxanthohumol

Enzyme [G]: OMT1 = chalcone O-methyltransferase: desmethylxanthohumol --> xanthohumol

Jiang et al succeeded in the biosynthesis of several flavonoids in Saccharomyces cerevisiae by the assembly of a plasmid containing three required enzymes (pKS2µHyg-PAL-4CL-CHS) and thereby showed the proof of principle. The activity of each enzyme was demonstrated and the presence of naringenin, which forms the product of the three enzymes( PAL, 4CL, CHS), was shown. [Jiang and Morgan, 2004]

The Molecular and Physiological Effects of Xanthohumol

Fig. 3: Structure of xanthohumol.

Inhibition of Metabolic Activation of Procarcinogens:

2-amino-3-methylimidazo[4,5-f]quinolone, found in cooked meat, verified as a procarcinogen in an ames salmonella mutagenicity test. The inhibition is probably a result of an inhibition of the cytochrome P 450 enzymes Cyp1A1, Cyp1B1 and Cyp1A2 (phase 1 enzymes). But in order to achieve a clear inhibition, plasma concentrations of 1 µM would be necessary. In a study with male rats oral administration of xanthohumol (50 mg/kg) led to concentration maximums of 65 -180 nM after 4 h. Improved resorption of xanthohumol could be a possible target for innovation [Yilmazer et al. 2001a, Miranda et al. 2000b, Henderson et al., 2000, Gerhauser et al., 2002].

Induction of Carcinogen-Detoxifying Enzymes (Phase 2 Enzymes):

P450-activated carcinogens get conjugated to endogenous ligands (gluthathione, glucoronic acid, acetate and sulfate) by phase 2 enzymes to facilitate excretion. Therefore the induction of phase 2 enzymes should enhance the protection against carcinogenesis. Xanthohumol cat concentrations of 2.1-10.1 µM could induce quinone reductase (detoxification of quinones by conversion to hydroquinones which can be conjugated) in hepatoma Hepa 1c1c7 cells. It was shown that xanthohumol could selectively induce quinone reductase without causing a transcriptional activation of Cyp1A1 [Miranda et al., 2000c, Gerhauser et al., 2002].

Inhibition of Tumor Growth at an Early Stage:

Xanthohumol showed an inhibition of the proliferation of breast cancer (MCF-7) and ovarian cancer (A-2780) in vitro at IC50 values of 13 and 0.52 µM [Miranda et al., 1999]. Furthermore xanthohumol can inhibit the endogenous prostaglandin synthesis through inhibition of cyclooxygenase (COX-1 and COX-2) with IC50 values of 17 and 42 µM. An increased prostaglandin production has been associated with the uncontrolled proliferation of tumor cells [Gerhauser et al., 2002]. Pharmacokinetic studies for xanthohumol based on beverages with an xanthohumol content of 50 mg/l in humans are part of actual research activities.

Antioxidant Activities:

Xanthohumol at 5 µM decreased conjugated diene formation as a measure for lipid peroxidation by more than 70 % after 5 h of incubation in an in vitro assay (protection of LDL from Cu2+ induced oxidation). Furthermore xanthohumol was shown to scavenge hydroxyl-, peroxyl- and superoxide anion radicals [Miranda et al., 2000c].

Results


BioBricks

The following BioBricks were constructed to achieve the production of xanthohumol.

Overview

Fig. 4: Metabolic pathway of xanthohumol and designed BioBricks.


BBa_K801090 and BBa_K801091 RFC10 compatible BioBricks encoding the enzyme PAL

Both RFC10 compatible BioBricks encode the enzyme phenylalanine ammonia lyase (PAL). BBa_K801090 contains the yeast consensus sequence (improved ribosome binding), BBa_K801091 does not. PAL is catalyzing the first reaction step of the xanthohumol biosynthesis pathway resulting in 4-coumarate.

Further Information:

  • NCBI
  • UniProt entry: P11544
  • E.C. Number: 4.3.1.25
  • Origin of the enzyme: Rhodosporidium toruloides

BBa_K801092 and BBa_K801093 RFC25 compatible BioBricks encode the enzyme 4CL

Both RFC25 compatible BioBricks encode the enzyme 4-coumarate-coenzyme A ligase (4CL). BBa_K801092 contains the yeast consensus sequence, BBa_K801093 does not.

Further Information:

  • NCBI
  • UniProt entry: Q42524
  • E.C. Number: 6.2.1.12
  • Origin of the enzyme: Arabidopsis thaliana

BBa_K801094 and BBa_K801095 RFC25 compatible BioBricks encoding the enzyme CHS

Both RFC25 compatible BioBricks encode the enzyme naringenin-chalcone synthase (CHS). BBa_K801094 contains the yeast consensus sequence, BBa_K801095 does not.

Further Information:

  • NCBI
  • UniProt entry: Q9FUB7
  • E.C. Number: 2.3.1.74
  • Origin of the enzyme: Hypericum androsaemum

BBa_K801096 RFC25 compatible BioBrick encoding the enzyme APT

This RFC25 compatible BioBrick encodes the enzyme aromatic prenyltransferase (APT).

Further Information:

  • NCBI
  • UniProt entry: E5RP65
  • E.C. Number: EC 2.5.1
  • Origin of the enzyme: Humulus lupulus

BBa_K801097 and BBa_K801098 RFC25 compatible BioBricks encoding the enzyme OMT1

Both RFC25 compatible BioBricks encode the enzyme O-methyltransferase 1 (OMT1). BBa_K801097 contains the yeast consensus sequence, BBa_K801095 does not.

Further Information:

  • NCBI
  • UniProt entry: B0ZB55
  • E.C. Number: EC 2.1.1
  • Origin of the enzyme: Humulus lupulus

Characterization


We have successfully cloned all 5 enzymes which are necessary for the biosynthesis of xanthohumol in pTUM104 as well as in pSB1C3. Except for APT each enzyme was designed in two versions: one with a proposed yeast consensus sequence and one without. In yeast this sequence should result in improved ribosome binding (TACACA) and was added 5’ of the start codon ATG. All BioBricks were sequenced. Sequences can be found in the registry of standard biological parts: BBa_K801090, BBa_K801091, BBa_K801092, BBa_K801093, BBa_K801094, BBa_K801095, BBa_K801096, BBa_K801097, BBa_K801098.


Our next goal is to prove enzyme expression via SDS-PAGE and Western Blot analysis. Afterwards activities will be tested in in-vitro assays to ensure the functionality of the 5 enzymes.

References


  • [Gerhauser et al., 2002] Gerhauser, C., Alt, A., Heiss, E., Gamal-Eldeen, A., Klimo, K., Knauft, J., Neu- mann, I., Scherf, H.-R., Frank, N., Bartsch, H., and Becker, H. (2002). Cancer chemopreventive activity of xanthohumol, a natural product derived from hop. Mol Cancer Ther, 1(11):959–69.
  • [Henderson et al., 2000] Henderson, M. C., Miranda, C. L., Stevens, J. F., Deinzer, M. L., and Buhler, D. R. (2000). In vitro inhibition of human p450 enzymes by prenylated flavonoids from hops, humulus lupulus. Xenobiotica, 30(3):235–51.
  • [Jiang and Morgan, 2004] Jiang, H. and Morgan, J. A. (2004). Optimization of an in vivo plant p450 monooxygenase system in Saccharomyces cerevisiae. Biotechnol Bioeng, 85(2):130–7.
  • [Miranda et al., 2000a] Miranda, C. L., Aponso, G. L., Stevens, J. F., Deinzer, M. L., and Buhler, D. R. (2000a). Prenylated chalcones and flavanones as inducers of quinone reductase in mouse hepa 1c1c7 cells. Cancer Lett, 149(1-2):21–9.
  • [Miranda et al., 1999] Miranda, C. L., Stevens, J. F., Helmrich, A., Henderson, M. C., Rodriguez, R. J., Yang, Y. H., Deinzer, M. L., Barnes, D. W., and Buhler, D. R. (1999). Antiproliferative and cytotoxic effects of prenylated flavonoids from hops (Humulus lupulus) in human cancer cell lines. Food Chem Toxicol, 37(4):271–85.
  • [Miranda et al., 2000b] Miranda, C. L., Stevens, J. F., Ivanov, V., McCall, M., Frei, B., Deinzer, M. L., and Buhler, D. R. (2000b). Antioxidant and prooxidant actions of prenylated and nonprenylated chalcones and flavanones in vitro. J Agric Food Chem, 48(9):3876–84.
  • [Miranda et al., 2000c] Miranda, C. L., Yang, Y. H., Henderson, M. C., Stevens, J. F., Santana-Rios, G., Deinzer, M. L., and Buhler, D. R. (2000c). Prenylflavonoids from hops inhibit the metabolic activation of the carcinogenic heterocyclic amine 2-amino-3-methylimidazo[4, 5-f]quinoline, mediated by cdna-expressed human cyp1a2. Drug Metab Dispos, 28(11):1297–302.
  • [Trantas et al., 2009] Trantas, E., Panopoulos, N., and Ververidis, F. (2009). Metabolic engineering of the complete pathway leading to heterologous biosynthesis of various flavonoids and stilbenoids in Saccharomyces cerevisiae. Metab Eng, 11(6):355–66.
  • [Yilmazer et al., 2001a] Yilmazer, M., Stevens, J. F., and Buhler, D. R. (2001a). In vitro glucuronidation of xanthohumol, a flavonoid in hop and beer, by rat and human liver microsomes. FEBS Lett, 491(3):252–6.
  • [Yilmazer et al., 2001b] Yilmazer, M., Stevens, J. F., Deinzer, M. L., and Buhler, D. R. (2001b). In vitro biotransformation of xanthohumol, a flavonoid from hops (Humulus lupulus), by rat liver microsomes. Drug Metab Dispos, 29(3):223–31.